Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 +/- Pembrolizumab vs TPC in HR+/HER2- Advanced Breast Cancer
NCT06312176Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 40
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in breast cancer, sponsored by Merck & Co.. Started Apr 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06312176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312176.